Lie T S, Kanda M, Kim W I, Holst A, Kawamura A, Biersack H J
Res Exp Med (Berl). 1976 May 15;167(2):171-83. doi: 10.1007/BF01851598.
53 LBNF1 kidneys were grafted into L-rats. 24 untreated recipients served as control and survived 16.1 +/- 1.7 days. 14 recipients were treated with 4 ml alloantiserum (ADS) each, and the other 15 animals with 4 ml ALS each. 9 and 10 of these 14 and 15 animals survived for more than 4 months. We performed GvH-reaction with spleen cells of these 19 animals. It showed normal cellular immune response. After splenectomy first donor specific skin was transplanted, 18 days later second skin of same origin (LBNF1) and 18' days after third party skin (LBufF1). The first grafts survived 13.1 +/- 1.9 days in the recipients of ADS treatment and 12.2 +/- 1.2 days in the recipients of ALS. Second skin grafts were rejected delayed in the former recipients as the first grafts, in the later more accelerated than the first grafts. The third grafts survived as the controls. Before and after skin grafting we could not detect lymphocytotoxin and hemagglutinin. The sera of animals with ADS therapy inhibited the spontaneous allorosette formation to 46.0 +/- 4.4% and of ALS therapy 37.7 +/- 9.2%. Our results suggest that after ALS treatment blocking antibodies were produced in the recipients and they cause the enhancement of kidney allograft.
将53个LBNF1品系大鼠的肾脏移植到L系大鼠体内。24只未接受治疗的受体作为对照,存活了16.1±1.7天。14只受体分别接受4毫升同种抗血清(ADS)治疗,另外15只动物分别接受4毫升抗淋巴细胞血清(ALS)治疗。这14只和15只动物中有9只和10只存活超过4个月。我们用这19只动物的脾细胞进行了移植物抗宿主反应(GvH反应)。结果显示细胞免疫反应正常。脾切除术后,首先移植供体特异性皮肤,18天后移植同来源(LBNF1)的第二块皮肤,在移植第三方皮肤(LBufF1)18天后进行。在接受ADS治疗的受体中,第一次移植的皮肤存活了13.1±1.9天,在接受ALS治疗的受体中存活了12.2±1.2天。在先前接受治疗的受体中,第二次皮肤移植的排斥反应与第一次移植一样延迟,而在后者中,排斥反应比第一次移植加速得更多。第三次移植的皮肤存活情况与对照组相同。在皮肤移植前后,我们均未检测到淋巴细胞毒素和血凝素。接受ADS治疗的动物血清将自发的异源玫瑰花结形成抑制到46.0±4.4%,接受ALS治疗的动物血清抑制到37.7±9.2%。我们的结果表明,接受ALS治疗后,受体产生了封闭抗体,它们导致了肾移植的增强。